Full Year 2025 PolyPeptide Group AG Earnings Call Transcript
Key Points
- PolyPeptide Group AG (PLYGF) achieved a 16% revenue increase at constant exchange rates in 2025, driven primarily by metabolic therapeutics.
- EBITDA margin improved significantly from 7.5% in 2024 to 12% in 2025, with a second-half margin reaching 19%.
- The company has enhanced its financing flexibility through strong operating cash flow and customer support, allowing for expanded financing options.
- Capacity expansions are on track, with the new laser cat capacity in Brain achieving optimal utilization, increasing potential revenues from $100 million to $125 million.
- PolyPeptide Group AG (PLYGF) has a strong market position with deep peptide expertise, working with 14 of the top 20 pharmaceutical players and having a rich pipeline of projects.
- Non-metabolic growth was limited to around 1%, partly due to exiting non-core businesses such as genetics and cosmetics.
- The company faces potential risks from the complex development and manufacturing processes, as well as geopolitical uncertainties.
- There were unrealized FX losses due to the revaluation of intercompany loans, impacting financial results with a EUR-21.2 million net result for 2025.
- Customer prepayments decreased to EUR27 million, indicating potential volatility in future funding from this source.
- The resignation of CFO Marc Augustin for personal reasons may lead to transitional challenges in financial leadership.
Ladies and gentlemen, welcome to the PolyPeptide's full-year 2025 business update and results presentation, conference call, and live webcast. I am Moira, the Chorus Call operator. (Operator Instructions) And the conference is being recorded. The presentation will be followed by a Q&A session. (Operator Instructions)
The conference must not be recorded for publication or broadcast. At this time, it's my pleasure to hand over to Tim Brandl, Financial Planning and IR. Please go ahead, sir.
Good morning, everyone, and welcome to our 2025 full-year results presentation. I am being joined today by our CEO, Juan José Gonzalez; and our CFO, Marc Augustin, who will take you through the presentation and will be open to take questions at the end.
Before we start, I would like to draw your attention to our usual disclaimer on page 2. For the Q&A, please follow the instructions on page 3. (Event Instructions) Moving on to the agenda, Juan José will start with a
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
